A candidate vaccine based on the hepatitis C E1 protein: tolerability and immunogenicity in healthy volunteers
Authors:
- Erik DeplaEDErik Depla
- Frank HulstaertFHFrank Hulstaert
- Leen TobbackLTLeen Tobback
- Stéphanie DincqSDStéphanie Dincq
- Jaques DesmetJDJaques Desmet
- Isabelle DesombereIDIsabelle Desombere
- Geert MaertensGMGeert Maertens
- 1 August 2004
- Vol. 22 (23-24) , 3080-3086
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- 247 Acute resolving infection after E1 but not after E2 prophylactic vaccination and heterologous challenge with 100 CID of HCV subtype 1B strain HC-J4Hepatology, 2003
- Natural history of chronic hepatitis CHepatology, 2002
- Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus InfectionNew England Journal of Medicine, 2002
- New therapeutic strategies for hepatitis CHepatology, 2002
- Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trialThe Lancet, 2001
- Hepatitis C Virus InfectionNew England Journal of Medicine, 2001
- Antibodies Against Hepatitis C Virus-Like Particles and Viral Clearance in Acute and Chronic Hepatitis CHepatology, 2000
- Long term response to interferon treatment in chronic hepatitis C patients is associated with a significant reduction in anti-E1 envelope antibody titersJournal of Medical Virology, 1999
- Serological and molecular analysis of hepatitis C virus envelope regions 1 and 2 during acute and chronic infections in chimpanzeesJournal of Medical Virology, 1997
- Lymphoproliferative responses to hepatitis C virus core, E1, E2, and NS3 in patients with chronic hepatitis C infection treated with interferon alfaHepatology, 1996